Motor, cognitive, and functional declines contribute to a single progressive factor in early HD

Overview of attention for article published in Neurology, November 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 7 news outlets
twitter: 6 X users
patent: 9 patents

googleplus: 1 Google+ user
guideline: 1 clinical guideline source

Readers on

mendeley: 176 Mendeley

So far, Altmetric has seen 7 news stories from 7 outlets.

Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression

BioSpace, 05 Sep 2025

8 min read Treatment with pridopidine slowed clinical progression and maintained function, cognition, and motor performance in…

Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression

Panhandle - News Channel Nebraska, 05 Sep 2025

Nature Medicine publishes Phase 3 data on pridopidine in early-stage Huntington’s Disease, highlighting impact on clinical…

News story from Finanz Nachrichten on Friday 05 September 2025

Finanz Nachrichten, 05 Sep 2025

Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression

AP News, 05 Sep 2025

NAARDEN, Netherlands

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 3 additional news stories.